Background/Aims: The aim of the present study was to investigate whether short children with normal growth hormone (GH) immunoreactivity, but reduced bioactivity (bio-inactive GH) could benefit from rhGH treatment as GH deficient (GHD) patients. Methods:We evaluated 12 pre-pubertal children (8 M, 4 F), with GH deficiency-like phenotype showing normal serum GH peak levels > 10 ng/ml), measured by immunofluorimetric assay (IFMA-GH), in contrast with a reduced GH bioactivity (bio-GH), evaluated using the Nb-2 cells. We also evaluated 15 age-matched GHD pre-pubertal children (11 M, 4 F) with serum GH peak < 5 ng/ml. Both groups were treated with rhGH therapy at the dose of 0.23 mg/kg/week s.c. Results: Serum bio-GH/IFMA-GH ratio at peaktime for each patient during the provocative test was significantly lower in bioinactive GH than in GHID children (0.29 vs. 2.05, p = 0.00001). Recombinant human GH therapy induced a significant (p < 0.001) increase in growth rate in both groups during the first 2 years. In the third year of treatment, while growth rate in GHD children is maintained, in bioinactive GH patients it decreases remaining, however higher compared to the pre-treatment one. Conclusions: Short rhGH therapy given to selected bioinactive GH children improve growth rate and might result in greater final adult height. Copyright (c) 2006 S. Karger AG, Basel.

Response to long-term growth hormone therapy in short children with reduced GH bioactivity / Travaglino, P; Buzi, F; Meazza, C; Pagani, S; Tinelli, C; Iughetti, Lorenzo; De Sanctis, V; Aimaretti, G; Poddighe, D; Barberi, S; Bozzola, M.. - In: HORMONE RESEARCH. - ISSN 0301-0163. - STAMPA. - 66:4(2006), pp. 189-194. [10.1159/000094483]

Response to long-term growth hormone therapy in short children with reduced GH bioactivity

IUGHETTI, Lorenzo;
2006

Abstract

Background/Aims: The aim of the present study was to investigate whether short children with normal growth hormone (GH) immunoreactivity, but reduced bioactivity (bio-inactive GH) could benefit from rhGH treatment as GH deficient (GHD) patients. Methods:We evaluated 12 pre-pubertal children (8 M, 4 F), with GH deficiency-like phenotype showing normal serum GH peak levels > 10 ng/ml), measured by immunofluorimetric assay (IFMA-GH), in contrast with a reduced GH bioactivity (bio-GH), evaluated using the Nb-2 cells. We also evaluated 15 age-matched GHD pre-pubertal children (11 M, 4 F) with serum GH peak < 5 ng/ml. Both groups were treated with rhGH therapy at the dose of 0.23 mg/kg/week s.c. Results: Serum bio-GH/IFMA-GH ratio at peaktime for each patient during the provocative test was significantly lower in bioinactive GH than in GHID children (0.29 vs. 2.05, p = 0.00001). Recombinant human GH therapy induced a significant (p < 0.001) increase in growth rate in both groups during the first 2 years. In the third year of treatment, while growth rate in GHD children is maintained, in bioinactive GH patients it decreases remaining, however higher compared to the pre-treatment one. Conclusions: Short rhGH therapy given to selected bioinactive GH children improve growth rate and might result in greater final adult height. Copyright (c) 2006 S. Karger AG, Basel.
2006
66
4
189
194
Response to long-term growth hormone therapy in short children with reduced GH bioactivity / Travaglino, P; Buzi, F; Meazza, C; Pagani, S; Tinelli, C; Iughetti, Lorenzo; De Sanctis, V; Aimaretti, G; Poddighe, D; Barberi, S; Bozzola, M.. - In: HORMONE RESEARCH. - ISSN 0301-0163. - STAMPA. - 66:4(2006), pp. 189-194. [10.1159/000094483]
Travaglino, P; Buzi, F; Meazza, C; Pagani, S; Tinelli, C; Iughetti, Lorenzo; De Sanctis, V; Aimaretti, G; Poddighe, D; Barberi, S; Bozzola, M.
File in questo prodotto:
Non ci sono file associati a questo prodotto.
Pubblicazioni consigliate

Licenza Creative Commons
I metadati presenti in IRIS UNIMORE sono rilasciati con licenza Creative Commons CC0 1.0 Universal, mentre i file delle pubblicazioni sono rilasciati con licenza Attribuzione 4.0 Internazionale (CC BY 4.0), salvo diversa indicazione.
In caso di violazione di copyright, contattare Supporto Iris

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11380/612116
Citazioni
  • ???jsp.display-item.citation.pmc??? 0
  • Scopus 9
  • ???jsp.display-item.citation.isi??? 9
social impact